PRTA
Prothena Corporation plc

2,002
Mkt Cap
$547.99M
Volume
504,462.00
52W High
$17.66
52W Low
$4.32
PE Ratio
-1.91
PRTA Fundamentals
Price
$9.93
Prev Close
$10.18
Open
$10.04
50D MA
$9.70
Beta
1.10
Avg. Volume
620,502.30
EPS (Annual)
-$2.27
P/B
1.81
Rev/Employee
$829,184.05
Loading...
Loading...
News
all
press releases
Quinn Opportunity Partners LLC Takes Position in Prothena Corporation plc $PRTA
Quinn Opportunity Partners LLC purchased a new position in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) in the second quarter, according to its most recent disclosure with the...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
Cantor Fitzgerald Increases Earnings Estimates for Prothena
Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for Prothena in a research report issued on Monday, November 10th...
MarketBeat·2d ago
News Placeholder
1,018,177 Shares in Prothena Corporation plc $PRTA Bought by Acadian Asset Management LLC
Acadian Asset Management LLC acquired a new position in Prothena Corporation plc (NASDAQ:PRTA - Free Report) in the second quarter, according to its most recent disclosure with the Securities and...
MarketBeat·2d ago
News Placeholder
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the...
Business Wire·4d ago
News Placeholder
What is HC Wainwright's Estimate for Prothena Q2 Earnings?
Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Stock analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Prothena in a note issued to investors on...
MarketBeat·5d ago
News Placeholder
Prothena (NASDAQ:PRTA) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Prothena (NASDAQ:PRTA - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·5d ago
News Placeholder
Prothena (NASDAQ:PRTA) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Prothena from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·6d ago
News Placeholder
Prothena (NASDAQ:PRTA) Price Target Raised to $30.00
HC Wainwright upped their target price on shares of Prothena from $20.00 to $30.00 and gave the company a "buy" rating in a research report on Friday...
MarketBeat·6d ago
News Placeholder
Prothena (NASDAQ:PRTA) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
Royal Bank Of Canada upped their price objective on shares of Prothena from $10.00 to $11.00 and gave the stock a "sector perform" rating in a report on Friday...
MarketBeat·6d ago
News Placeholder
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Zacks·8d ago

Latest PRTA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.